NO to breast: When, why and why not?

Current Pharmaceutical Design

Volumn 16, Issue 4, 2010, Pages 451-462

  Pervin, Shehla ^a,b   Chaudhuri, Gautam ^a,c   Singh, Rajan ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Breast cancer; Estrogen; Inflammation; Nitric oxide; Oxidative stress; Proliferation

Indexed keywords

ALPHA NAPHTHOFLAVONE; ASCORBIC ACID; BUTYLATED HYDROXYANISOLE; CURCUMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; DNA POLYMORPHISM; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; MYOEPITHELIUM CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DISEASE COURSE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS;

EID: 77949431180     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790232130     Document Type: Review

References (170)

1. Brüne B. The intimate relation between nitric oxide and superoxide in apoptosis and cell survival. Antioxid Redox Signal 2005; 7: 497-507.
2. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 2009; 14: 1-18.
3. Demple B. Signal transduction by nitric oxide in cellular stress responses. Mol Cell Biochem 2002; 234-35: 11-8.
4. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002; 53: 503-14.
5. Bryan NS. Cardioprotective actions of nitrite therapy and dietary considerations. Front Biosci 2009; 14: 4793-808.
6. Gatti G, Simsek S, Zurrida S, Kurne A, Giannetti I, Demirer S, et al. Possible role of nitric oxide in the biology of breast carcinoma: review of the available literature. Breast 2004; 13: 1-6.
7. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004; 101: 8894-9.
8. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci USA 2001; 98: 3583-8.
9. Paquette B, Cantin AM, Kocsis-Bédard S, Barry S, Lemay R, Jay-Gerin JP. In vitro generation of peroxynitrite by 2- and 4-hydroxyestrogens in the presence of nitric oxide. Chem Res Toxicol 2001; 14: 547-54.
10. Folkes LK, Wardman P. Kinetics of the reaction between nitric oxide and glutathione: implications for thiol depletion in cells. Free Radic Biol Med 2004; 37: 549-56.
11. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 1998; 17: 107-18.
12. Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 2004; 26: 321-9.
13. Pance A. Nitric oxide and hormones in breast cancer: allies or enemies? Future Oncol 2006; 2: 275-88.
14. Jadeski LC, Chakraborty C, Lala PK. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogenactivated protein kinase. Int J Cancer 2003; 106: 496-504.
15. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995; 72: 41-4.
16. Vakkala M, Paakko P, Soini Y. eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 2000; 17: 667-71.
17. Martin JH, Begum S, Alalami O, Harrison A, Scott KW. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 2000; 21: 90-7.
18. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007; 6: 2010-8.
19. Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K, et al. Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinogenesis 2002; 33: 56-65.
20. Gould KA, Tochacek M, Schaffer BS, Reindl TM, Murrin CR, Lachel CM, et al. Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 2004; 168: 2113-25.
21. Kim SW, Wu G. Regulatory role for amino acids in mammary gland growth and milk synthesis. Amino Acids 2009; 37: 89-95.
22. Onoda M, Inano H. Localization of nitric oxide synthases and nitric oxide production in the rat mammary gland. J Histochem Cytochem 1998; 46: 1269-78.
23. Islam MS, Matsumoto M, Tsuchida K, Oka T, Kanouchi H, Suzuki S. Immunohistochemical localization of nitric oxide synthase (NOS) in mouse mammary gland during reproductive cycle. J Vet Med Sci 2009; 71: 945-9.
24. Lacasse P, Farr VC, Davis SR, Prosser CG. Local secretion of nitric oxide and the control of mammary blood flow. J Dairy Sci 1996; 79: 1369-74.
25. Schwertfeger KL, Rosen JM, Cohen DA. Mammary gland macrophages: pleiotropic functions in mammary development. J Mammary Gland Biol Neoplasia 2006; 11: 229-38.
26. Loibl S, von Minckwitz G, Weber S, Sinn HP, Schini-Kerth VB, Lobysheva I, et al. Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer 2002; 95: 1191-8.
27. Loibl S, Strank C, von Minckwitz G, Sinn HP, Buck A, Solbach C, et al. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast 2005; 14: 230-5.
28. Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer 2005; 41: 265-71.
29. Vakkala M, Kahlos K, Lakari E, Pääkkö P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000; 6: 2408-16.
30. Valkovi?? T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonji?? N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 2002; 440: 583-8.
31. Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch. 2005; 447: 24-30.
32. Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, et al. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol 2005; 58: 600-4.
33. Brennan PA, Sharma S, Bowden JR, Umar T. Expression of inducible nitric oxide synthase in bone metastases. Eur J Surg Oncol 2003; 29: 619-23.
34. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155: 1381-90.
35. Ellies LG, Fishman M, Hardison J, Kleeman J, Maglione JE, Manner CK, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003; 106: 1-7.
36. Davie SA, Maglione JE, Manner CK, Young D, Cardiff RD, MacLeod CL, et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 2007; 16: 193-201.
37. Gauthier N, Lohm S, Touzery C, Chantôme A, Perette B, Reveneau S, et al. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 2004; 25: 1559-65.
38. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, et al The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009; 45: 1780-7.
39. Frasor J, Weaver AE, Pradhan M, Mehta K. Synergistic upregulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 2008; 149: 6272-9.
40. Roberts RA, Laskin DL, Smith CV, Robertson FM, Allen EM, Doorn JA, et al. Nitrative and oxidative stress in toxicology and disease. Toxicol Sci 2009; 112: 4-16.
41. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
42. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.
43. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-85.
44. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003; 100: 143-8.
45. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008; 19: 65-7.
46. Karihtala P, Kinnula VL, Soini Y. Antioxidative response for nitric oxide production in breast carcinoma. Oncol Rep 2004; 12: 755-9.
47. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1784-94.
48. Li Y, Ambrosone CB, McCullough MJ, Ahn J, Stevens VL, Thun MJ, et al. Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. Carcinogenesis 2009; 30: 777-84.
49. Onoda M, Inano H. Effect of curcumin on the production of nitric oxide by cultured rat mammary gland. Nitric Oxide 2000; 4: 505-15.
50. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C, et al. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 2008; 29: 779-89.
51. Chakrabarti S, Lekontseva O, Davidge ST. Estrogen is a modulator of vascular inflammation. IUBMB Life 2008; 60: 376-82.
52. Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: implications for hormonal carcinogenesis. Free Radic Biol Med 1998; 24: 341-8.
53. Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, et al. Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 2008; 232: 78-85.
54. Mense SM, Singh B, Remotti F, Liu X, Bhat HK. Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis 2009; 30: 1202-8.
55. Singh B, Mense SM, Remotti F, Liu X, Bhat HK. Antioxidant butylated hydroxyanisole inhibits estrogen-induced breast carcinogenesis in female ACI rats. J Biochem Mol Toxicol 2009; 23: 202-11.
56. Oestergaard MZ, Tyrer J, Cebrian A, Shah M, Dunning AM, Ponder BA, et al. Interactions between genes involved in the antioxidant defense system and breast cancer risk. Br J Cancer 2006; 95: 525-31.
57. He C, Tamimi RM, Hankinson SE, Hunter DJ, Han J. A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk. Breast Cancer Res Treat 2009; 113: 585-94.
58. Lin SC, Chou YC, Wu MH, Wu CC, Lin WY, Yu CP, et al. Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk. Eur J Cancer Prev 2005; 14: 257-61.
59. Ahn J, Ambrosone CB, Kanetsky PA, Tian C, Lehman TA, Kropp S, et al. Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer. Clin Cancer Res 2006; 12: 7063-70.
60. Bica CG, de Moura da Silva LL, Toscani NV, da Cruz IB, Sá G, Graudenz MS, et al. MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res 2009; 15: 19-24.
61. Slanger TE, Chang-Claude J, Wang-Gohrke S. Manganese superoxide dismutase Ala-9Val polymorphism, environmental modifiers, and risk of breast cancer in a German population. Cancer Causes Control 2006; 17: 1025-31.
62. Teoh ML, Fitzgerald MP, Oberley LW, Domann FE. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. Cancer Res 2009; 69: 6355-63.
63. Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, et al. Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 1082-7.
64. Pryor WA, Houk KN, Foote CS, Fukuto JM, Ignarro LJ, Squadrito GL, et al. Free radical biology and medicine: it's a gas, man! Am J Physiol Regul Integr Comp Physiol 2006; 291: R491-511.
65. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
66. Lancaster JR Jr. Protein cysteine thiol nitrosation: maker or marker of reactive nitrogen species-induced non-erythroid cellular signaling? Nitric Oxide 2008; 19: 68-72.
67. Shinyashiki M, Pan CJ, Lopez BE, Fukuto JM. Inhibition of the yeast metal reductase heme protein fre1 by nitric oxide (NO): a model for inhibition of NADPH oxidase by NO. Free Radic Biol Med 2004; 37: 713-23.
68. Le Moan N, Tacnet F, Toledano MB. Protein-thiol oxidation, from single proteins to proteome-wide analyses. Methods Mol Biol 2009; 476: 175-92.
69. Domenico R. Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies. Curr Pharm Des 2004; 10: 1667-76.
70. Forman HJ, Torres M. Redox signaling in macrophages. Mol Aspects Med 2001; 22: 189-216.
71. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008; 35: 41-50.
72. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-56.
73. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J) 2007; 83: S192-203.
74. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009 Sep 3. [Epub ahead of print]
75. Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME. Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention. Front Biosci 2009; 1: 329-57.
76. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009; 20: 193-201.
77. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008; 105: 956-64.
78. Berstein LM, Kovalevskij AY, Poroshina TE, Kotov AV, Kovalenko IG, Tsyrlina EV, et al. Signs of proinflammatory/ genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J Cancer 2007; 121: 514-9.
79. Dohi K, Satoh K, Mihara Y, Nakamura S, Miyake Y, Ohtaki H, et al. Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma 2006; 23: 1591-9.
80. Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007; 8: 279-8.
81. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155: 1381-90.
82. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30-9.
83. Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res 2007; 67: 2849-56.
84. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003; 4: 31-9.
85. Harris SR, Schoeffner DJ, Yoshiji H, Thorgeirsson UP. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002; 179: 95-101.
86. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006; 12: 1201-7.
87. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98: 2604-9.
88. Gélinas DS, Bernatchez PN, Rollin S, Bazan NG, Sirois MG. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br J Pharmacol 2002; 137: 1021-30.
89. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 2006; 96: 209-15.
90. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008; 111: 157-63.
91. Yin T, Ma X, Zhao L, Cheng K, Wang H. Angiotensin II promotes NO production, inhibits apoptosis and enhances adhesion potential of bone marrow-derived endothelial progenitor cells. Cell Res 2008; 18: 792-9.
92. de Nigris F, Balestrieri ML, Williams-Ignarro S, D'Armiento FP, Lerman LO, Byrns R, et al. Therapeutic effects of autologous bone marrow cells and metabolic intervention in the ischemic hind limb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. J Cardiovas Pharmacol 2007; 50: 424-33.
93. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004; 109: 2454-61.
94. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98: 12485-90.
95. Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007; 67: 289-99.
96. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007; 98: 1889-92.
97. Liu Z, Yu X, Shaikh ZA. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol 2008; 228: 286-94.
98. Pervin S, Singh R, Chaudhuri G. Nitric oxide, N omega-hydroxy-L-arginine and breast cancer. Nitric Oxide 2008; 19: 103-6.
99. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006; 15: 718-27.
100. Deng W, Jiang X, Mei Y, Sun J, Ma R, Liu X, et al. Role of ornithine decarboxylase in breast cancer. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 235-43.
101. Falcone S, Mauro L, de Rose G, Paolucci C, Sciorati C, Ando S, et al. Nitric oxide regulates oestrogen-activated signalling pathways at multiple levels through cyclic GMP-dependent recruitment of insulin receptor substrate 1. Biochem J 2002; 366: 165-73.
102. Oktem G, Bilir A, Selvi N, Yurtseven ME, Vatansever S, Ates U, et al. Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. Oncol Res 2006; 16: 195-203.
103. Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. Semin Thromb Hemost 2007; 33: 667-72.
104. Radisavljevic Z. Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J Cell Biochem 2004; 92: 1-5.
105. Hefler LA, Grimm C, Lantzsch T, Lampe D, Koelbl H, Lebrecht A, et al. Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat 2006; 98: 151-5.
106. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11: 719-25.
107. Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 2006; 107: 2245-53.
108. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX, et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 2005; 12: 177-82.
109. Royo JL, Moreno-Nogueira JA, Galán JJ, González- Martín A, Ruiz A, González-Mancha R, et al. Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study. Breast Cancer Res Treat 2006; 100: 331-3.
110. Moreno H Jr. Genetic polymorphisms and haplotypes of eNOS in breast cancer. Breast Cancer Res Treat 2008; 109: 181-2.
111. Choi JY, Lee KM, Noh DY, Ahn SH, Lee JE, Han W, et al. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 2006; 100: 213-8.
112. Schneider BP, Radovich M, Flockhart DA, Carpenter JS, Li L, Robarge JD, et al. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. Breast Cancer Res Treat 2009; 116: 543-9.
113. Cavalieri EL, Rogan EG. A unified mechanism in the initiation of cancer. Ann N Y Acad Sci 2002; 959: 341-54.
114. Adamovic T, Roshani L, Chen L, Schaffer BS, Helou K, Levan G, et al. Nonrandom pattern of chromosome aberrations in 17betaestradiol-induced rat mammary tumors: indications of distinct pathways for tumor development. Genes Chromosomes Cancer 2007; 46: 459-69.
115. Mills LH, Yu J, Xu XM, Lee AJ, Zhu BT. Naturally-occurring estradiol-17beta-fatty acid esters, but not estradiol-17beta, preferentially induce mammary tumorigenesis in female rats: implications for an important role in human breast cancer. Toxicol Appl Pharmacol 2008; 229: 332-41.
116. Martin JH, Alalami O, van den Berg HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett 1999; 144: 65-74.
117. Nakatani K, Horinouchi J, Yabu Y, Wada H, Nobori T. Expression of endothelial nitric oxide synthase is induced by estrogen with glycogen synthase 3beta phosphorylation in MCF-7 cells. Oncol Rep 2004; 12: 833-6.
118. Duckles SP, Krause DN. Cerebrovascular effects of oestrogen: multiplicity of action. Clin Exp Pharmacol Physiol 2007; 34: 801-8.
119. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002; 64: 749-74.
120. Chambliss KL, Yuhanna IS, Mineo C, Liu P, German Z, Sherman TS, et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 2000; 87: E44-52.
121. Joy S, Siow RC, Rowlands DJ, Becker M, Wyatt AW, Aaronson PI, et al. The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem 2006; 281: 27335-45.
122. Binder C, Schulz M, Hiddemann W, Oellerich M. Caspaseactivation and induction of inducible nitric oxide-synthase during TNF alpha-triggered apoptosis. Anticancer Res 1999; 19: 1715-20.
123. Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci USA 2008; 105: 3527-32.
124. Ruhlen RL, Willbrand DM, Besch-Williford CL, Ma L, Shull JD, Sauter ER. Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Res Treat 2009; 117: 517-24.
125. Li SA, Weroha SJ, Tawfik O, Li JJ. Prevention of solely estrogeninduced mammary tumors in female ACI rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 2002; 175: 297-305.
126. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004; 555: 107-19.
127. Tschugguel W, Schneeberger C, Unfried G, Czerwenka K, Weninger W, Mildner M, et al. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res Treat 1999; 56: 145-51.
128. Reveneau S, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint-Giorgio V, et al. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 1999; 79: 1215-25.
129. Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 2003; 50: 49-59.
130. Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, et al. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 2004; 64: 8015-21.
131. Yin MB, Li ZR, Tóth K, Cao S, Durrani FA, Hapke G, et al. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxiainducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene 2006; 25: 2509-19.
132. Shao ZM, Radziszewski WJ, Barsky SH. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett 2000; 157: 133-44.
133. Sun H, Gutierrez P, Jackson MJ, Kundu N, Fulton AM. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother 2000; 23: 208-14.
134. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginasedependent pathways. Cancer Res 2007; 67: 7386-94.
135. Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 1996; 59: 797-803.
136. Cooney R, Hynes SO, Duffy AM, Sharif F, O'Brien T. Adenoviralmediated gene transfer of nitric oxide synthase isoforms and vascular cell proliferation. J Vasc Res 2006; 43: 462-72.
137. Pervin S, Tran AH, Zekavati S, Fukuto JM, Singh R, Chaudhuri G. Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis. Cancer Res 2008; 68: 4862-74.
138. Pervin S, Singh R, Freije WA, Chaudhuri G. MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer. Cancer Res 2003; 63: 8853-60.
139. Pervin S, Singh R, Chaudhuri G. Nitric-oxide-induced Bax integration into the mitochondrial membrane commits MDA-MB-468 cells to apoptosis: essential role of Akt. Cancer Res 2003; 63: 5470-9.
140. Xie K, Fidler IJ. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 1998; 17: 55-75.
141. Albina JE. On the expression of nitric oxide synthase by human macrophages. Why no NO? J Leukoc Biol 1995; 58: 643-9.
142. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994; 70: 847-9.
143. Heller A. Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. Chem Med Chem 2008; 3: 1493-9.
144. Mitani T, Terashima M, Yoshimura H, Nariai Y, Tanigawa Y. TGF-beta1 enhances degradation of IFN-gamma-induced iNOS protein via proteasomes in RAW 264.7 cells. Nitric Oxide 2005; 13: 78-87.
145. Straus B, Cepelak I, Festa G. Arginase, a new marker of mammary carcinoma. Clin Chim Acta 1992; 210: 5-12.
146. Polat MF, Taysi S, Polat S, Böyük A, Bakan E. Elevated serum arginase activity levels in patients with breast cancer. Surg Today 2003; 33: 655-61.
147. Park KG, Heys SD, Harris CI, Steele RJ, McNurlan MA, Eremin O, et al. Arginine metabolism in benign and malignant disease of breast and colon: evidence for possible inhibition of tumorinfiltrating macrophages. Nutrition 1991; 7: 185-8.
148. Maggini S, Stoecklin-Tschan FB, Mörikofer-Zwez S, Walter P. New kinetic parameters for rat liver arginase measured at nearphysiological steady-state concentrations of arginine and Mn2+. Biochem J 1992; 283: 653-60.
149. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 2007; 137: 1616S-20S.
150. Erbas H, Aydogdu N, Usta U, Erten O. Protective role of carnitine in breast cancer via decreasing arginase activity and increasing nitric oxide. Cell Biol Int 2007; 31: 1414-9.
151. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001; 61: 1100-6.
152. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000; 60: 3305-12.
153. Singh R, Pervin S, Wu G, Chaudhuri G. Activation of caspase-3 activity and apoptosis in MDA-MB-468 cells by N(omega)-hydroxy-L-arginine, an inhibitor of arginase, is not solely dependent on reduction in intracellular polyamines. Carcinogenesis 2001; 22: 1863-9.
154. Singh R, Pervin S, Chaudhuri G. Caspase-8-mediated BID cleavage and release of mitochondrial cytochrome c during Nomega-hydroxy-L-arginine-induced apoptosis in MDA-MB-468 cells. Antagonistic effects of L-ornithine. J Biol Chem 2002; 277: 37630-6.
155. Olszanecki R, Marcinkiewicz J. Taurine chloramine and taurine bromamine induce heme oxygenase-1 in resting and LPSstimulated J774.2 macrophages. Amino Acids 2004; 27: 29-35.
156. Beeharry N, Chambers JA, Faragher RG, Garnett KE, Green IC. Analysis of cytokine-induced NO-dependent apoptosis using RNA interference or inhibition by 1400W. Nitric Oxide 2004; 10: 112-8.
157. Moselhy SS, Al mslmani MA. Chemopreventive effect of lycopene alone or with melatonin against the genesis of oxidative stress and mammary tumors induced by 7,12 dimethyl(a)benzanthracene in sprague dawely female rats. Mol Cell Biochem 2008; 319: 175-80.
158. Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu LM, et al. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 2009; 113: 275-80.
159. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, et al. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 2009; 45: 2077-86.
160. Carli CB, de Matos DC, Lopes FC, Maia DC, Dias MB, Sannomiya M, et al. Isolated flavonoids against mammary tumour cells LM2. Z Naturforsch C 2009; 64: 32-6.
161. Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res 2008; 10: R44.
162. Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 2008; 19: 199-204.
163. Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67: 1282-90.
164. Pervin S, Singh R, Gau CL, Edamatsu H, Tamanoi F, Chaudhuri G. Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. Cancer Res 2001; 61: 4701-6.
165. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217-24.
166. McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, et al. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14: 246-55.
167. Worthington J, Robson T, Scott S, Hirst D. Valuation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Gene Ther 2005; 12: 1417-23.
168. Al Moustafa AE, Kassab A, Darnel A, Yasmeen A. High-risk HPV/ErbB-2 interaction on E-cadherin/catenin regulation in human carcinogenesis. Curr Pharm Des 2008; 14(22): 2159-72.
169. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008; 14(28): 3020-32.
170. Nichols WW, Epstein BJ. Actions of selected cardiovascular hormones on arterial stiffness and wave reflections. Curr Pharm Des 2009; 15(3): 304-20.